Our findings suggest that SNPs involved in cGAS-STING-mediated type I interferon pathway may influence DLBCL susceptibility, treatment response, and prognosis, highlighting their potential as biomarkers for risk stratification and for guiding individualized disease monitoring. Here, CGAS is linked to diffuse large B-cell lymphoma.